Angiotensin II AT1 Receptor Antagonists
Journal of Medicinal Chemistry, 2006, Vol. 49, No. 5 1535
M.; Bailey, T. K.; Vice, G.; Cobuzzi, A.; Lai, F.; Mellish, N.
Synthesis and Biological Evaluation of the Potent Isoxazolidinyl
Angiotensin II Receptor Antagonist CL332,877 and Its Enantiomers.
Bioorg. Med. Chem. Lett. 1994, 4, 1709-1714. (e) Levin, J. I.;
Venkatesan, A. M.; Chan, P. S.; Bailey, T. K.; Vice, G.; Coupet, J.
6-Substituted Quinazolinone Angiotensin II Receptor Antagonists.
Bioorg. Med. Chem. Lett. 1994, 4, 1819-1824. (f) de Laszlo, S. E.;
Quagliato, C. S.; Greenlee, W. J.; Patchett, A. A.; Chang, R. S. L.;
Lotti, V. J.; Chen, T.-B.; Scheck, S. A.; Faust, K. A.; Kivlighn, S.
S.; Schorn, T. S.; Zingaro, G. J.; Siegl, P. K. S. A Potent, Orally
Active, Balanced Affinity Angiotensin II AT1 Antagonist and AT2
Binding Inhibitor. J. Med. Chem. 1993, 36, 3207-3210. (g) Levin,
J. I.; Chan, P. S.; Bailey, T.; Katocs, A. S.; Venkatesan, A. M. The
Synthesis of 2,3-Dihydro-4(1H)-quinazolinone Angiotensin II Recep-
tor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1141-1146. (h)
Allen, E. E.; de Laszlo, S. E.; Huang, S. X.; Quagliato, C. S.;
Greenlee, W. J.; Chang R. S. L.; Chen T.-B.; Faust, K. A.; Lotti, V.
J. Quinazolinones 1: Design and Synthesis of Potent Quinazolinone-
Containing AT1-Selective Angiotensin-II Receptor Antagonists.
Bioorg. Med. Chem. Lett. 1993, 3, 1293-1298.
Based Angiotensin II Receptor Antagonists. J. Med. Chem. 1991,
34, 2919-2922. (c) Krovat, E. M.; Langer, T. Non-Peptide Angio-
tensin II Receptor Antagonists: Chemical Feature Based Pharma-
cophore Identification. J. Med. Chem. 2003, 46, 716-726.
(23) Kurogi, Y.; Guner, O. F. Pharmacophore Modeling and Three-
Dimensional Database Searching for Drug Design Using Catalyst.
Curr. Med. Chem. 2001, 8, 1035-1055.
(24) Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational
Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf.
Comput. Sci. 1995, 35, 285-294.
(25) Barker, S.; Kapas, S.; Fluck, R. J.; Clark, A. J. L. Effects of the
Selective Protein Kinase C Inhibitor Ro 31-7549 on Human Angio-
tensin II Receptor Desensitization and Intracellular Calcium Release.
FEBS Lett. 1995, 369, 263-266.
(26) Bremner, J. B.; Coban, B.; Griffith, R.; Groenewoud, K. M.; Yates,
B. F. Ligand Design for R1 Adrenoceptor Subtype Selective
Antagonists. Bioorg. Med. Chem. 2000, 8, 201-214.
(27) Miyoshi, S.; Ishikawa, H.; Kaneko, T.; Fukui, F.; Tanaka, H.;
Maruyama, S. Structures and Activity of Angiotensin-Converting
Enzyme Inhibitors in an Alpha-Zein Hydrolysate. Agric. Biol. Chem.
1991, 55, 1313-1318.
(14) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.;
Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M.
Nonpeptide Angiotensin II Receptor Antagonists: The Next Genera-
tion in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-
656.
(15) (a) Cottineau, B.; Toto, P.; Marot, C.; Pipaud, A.; Chenault, J.
Synthesis and Hypoglycemic Evaluation of Substituted Pyrazole-4-
carboxylic Acids. Bioorg. Med. Chem. Lett. 2002, 12, 2105-2108.
(b) Mederski, W. W. K. R.; Dorsch, D.; Bokel, H.-H.; Beier, N.;
Lues, I.; Schelling, P. Non-Peptide Angiotensin II Receptor Antago-
nists: Synthesis and Biological Activity of a Series of Novel 4,5-
Dihydro-4-oxo-3H-imidazo[4,5-c]pyridine Derivatives. J. Med. Chem.
1994, 37, 1632-1645. (c) Hoover, J. R. E.; Chow, A. W.; Stedman,
R. J.; Hall, N. M.; Greenberg, H. S.; Dolan, M. M.; Ferlauto, R. J.
Semisynthetic Penicillins. I. 2-Biphenylylpenicillins. J. Med. Chem.
1964, 7, 245-251.
(16) Adams, G. L.; Graybill, T. L.; Sanchez, R. M.; Magaard, V. W.;
Burton, G.; Rivero, R. A. A Convenient ‘Catch and Release’
Synthesis of Fused 2-Alkylthio-pyrimidinones Mediated by Polymer-
Bound BEMP. Tetrahedron Lett. 2003, 44, 5041-5045.
(17) McCarty, J. E.; Haines, E. L.; VanderWerf, C. A. Synthesis of Some
Thioquinazolones of Interest as Potential Ataractic Agents. J. Am.
Chem. Soc. 1960, 82, 964-966.
(28) (a) Lew, M. J.; Ziogas, J.; Christopoulos, A. Dynamic Mechanisms
of Non-Classical Antagonism by Competitive AT1 Receptor An-
tagonists. Trends Pharmacol. Sci. 2000, 21, 376-381. (b) Lew, M.
J.; Christopoulos, A.; Ziogas, J. Non-Surmountable Antagonism:
Transcending Steady StatesResponse from Lew et al. Trends
Pharmacol. Sci. 2001, 22, 65-66. (c) Verheijen, I.; De Backer, J.-
P.; Vanderheyden, P.; Vauquelin, G. A Two-State Model of
Antagonist-AT1 Receptor Interaction: Further Support by Binding
Studies at Low Temperature. Biochem. Pharmacol. 2003, 65, 1339-
1341. (d) Lew, M. J.; Ziogas, J. The Two-State Model of Antagonist-
AT1 Receptor Interaction: An Hypothesis Defended but Not Tested.
Biochem. Pharmacol. 2004, 67, 397-399.
(29) (a) Vauquelin, G.; Morsing, P.; Fierens, F. L. P.; De Backer, J.-P.;
Vanderheyden, P. M. L. A Two-State Receptor Model for the
Interaction Between Angiotensin II Type 1 Receptors and Non-
Peptide Antagonists. Biochem. Pharmacol. 2001, 61, 277-284. (b)
Lemay, J.; Hou, Y.; deBlois, D. Evidence That Nitric Oxide Regulates
AT1-Receptor Agonist and Antagonist Efficacy in Rat Injured Carotid
Artery. J. CardioVas. Pharm. 2000, 35, 693-699. (c) Pantev, E.;
Stenman, E.; Wackenfors, A.; Edvinsson, L.; Malmsjo, M. Com-
parison of the Antagonistic Effects of Different Angiotensin II
Receptor Blockers in Human Coronary Arteries. Eur. J. Heart Fail.
2002, 4, 699-705.
(18) (a) Ji, H.; Leung, M.; Zhang, Y.; Catt, K. J.; Sandberg, K. Differential
Structural Requirements for Specific Binding of Nonpeptide and
Peptide Antagonists to the AT1 Angiotensin Receptor. J. Biol. Chem.
1994, 269, 16533-16536. (b) Li, Q.; Pfaffendorf, M.; van Zwieten,
P. A. Different Types of Antagonism by Losartan and Irbesartan on
the Effects of Angiotensin II and Its Degradation Products in Rabbit
Arteries. Fundam. Clin. Pharm. 2001, 15, 143-150.
(30) Takezako, T.; Gogonea, C.; Saad, Y.; Noda, K.; Karnik, S. S.
“Network Leaning” as a Mechanism of Insurmountable Antagonism
of the Angiotensin II Type 1 Receptor by Non-Peptide Antagonists.
J. Biol. Chem. 2004, 279, 15248-15257.
(31) Schoen, W. R.; Pisano, J. M.; Prendergast, K.; Wyvratt, M. J.; Fisher,
M. H.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Smith, R. G.; Ball,
R. G. A Novel 3-Substituted Benzazepinone Growth Hormone
Secretagogue (L-692, 429). J. Med. Chem. 1994, 37, 897-906.
(32) Carini, D. J.; Duncia, J. J. V. European Patent EP 253310, 1988.
(33) Duncia, J. V.; Pierce, M. E.; Santella, J. B. Three Synthetic Routes
to a Sterically Hindered Tetrazole. A New One-Step Mild Conversion
of an Amide into a Tetrazole. J. Org. Chem. 1991, 56, 2395-2400.
(34) (a) Bogert, M. T.; Scatchard, G. Researches on Quinazolines. XXXIII.
A New and Sensitive Indicator for Acidimetry and Alkalimetry, and
for the Determination of Hydrogen-ion Concentrations between the
Limits of 6 and 8 on the Sorensen Scale. J. Am. Chem. Soc. 1916,
38, 1606-1615. (b) Lange, N. A.; Sheibley, F. E. Benzoylene Urea
[2,4(1,3)-Quinazolinedione]. Organic Syntheses; Wiley: New York,
1943; Collect. Vol. II, pp 79-81.
(35) Gutcait, A.; Wang, K.-C.; Liu, H.-W.; Chern, J.-W. Studies on
Quinazolines. 6. Asymmetric Synthesis of (S)-(+)- and (R)-(-)-3-
[[4-(2-Methoxyphenyl)piperazin-1-yl]methyl]-5-methylthio-2,3-dihy-
droimidazo[1,2-c]quinazolines. Tetrahedron: Asymmetry 1996, 7,
1641-1648.
(36) Liljefors, T.; Pettersson, I. Computer-aided Development and Use
of Three-Dimensional Pharmacophore Models. In Textbook of Drug
Design and DiscoVery, 3rd ed.; Krogsgaard-Larsen, P., Liljefors, T.,
Madsen, U., Eds.; Taylor and Francis Inc.: New York, 2002; pp
86-116.
(19) (a) Bernhart, C. A.; Perreaut, P. M.; Ferrari, B. P.; Muneaux, Y. A.;
Assens, J.-L. A.; Clement, J.; Haudricourt, F.; Muneaux, C. F.;
Taillades, J. E.; Vignal, M.-A.; Gougat, J.; Guiraudou, P. R.; Lacour,
C. A.; Roccon, A.; Cazaubon, C. F.; Brelie`re, J.-C.; Le Fur, G.;
Nisato, D. A New Series of Imidazolones: Highly Specific and Potent
Nonpeptide AT1 Angiotensin II Receptor Antagonists. J. Med. Chem.
1993, 36, 3371-3380. (b) Quan, M. L.; DeLucca, I.; Boswell, G.
A.; Chiu, A. T.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M.
W. M. Imidazolinones as Nonpeptide Angiotensin II Receptor
Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1527-1530. (c)
Ferrari, B.; Taillades, J.; Perreaut, P.; Bernhart, C.; Gougat, J.;
Guiraudou, P.; Cazaubon, C.; Roccon, A.; Nisato, D.; Le Fur, G.;
Brelie`re, J. C. Development of Tetrazole Bioisosteres in Angiotensin
II Antagonsists. Bioorg. Med. Chem. Lett. 1994, 4, 45-50.
(20) (a) Sachinidis, A.; El-Haschimi, K.; Ko, Y.; Seul, C.; Epping, P.;
Vetter, H. Carbocyclic Thromboxane A2 Enhances the Angiotensin
II-Induced DNA Synthesis in Smooth Muscle Cells. Eur. J. Phar-
macol. 1996, 307, 121-124. (b) Kubo, K.; Kohara, Y.; Imamiya,
E.; Sugiura, Y.; Inada, Y.; Furukawa, Y.; Nishikawa, K.; Naka, T.
Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and
Biological Activity of Benzimidazolecarboxylic Acids. J. Med. Chem.
1993, 36, 2182-2195.
(21) Brousil, J. A.; Burke, J. M. Olmesartan Medoxomil: An Angiotensin
II-Receptor Blocker. Clin. Ther. 2003, 25, 1041-1055.
(22) (a) Prendergast, K.; Adams, K.; Greenlee, W. J.; Nachbar, R. B.;
Patchett, A. A.; Underwood, D. J. Derivation of a 3D Pharmacophore
Model for the Angiotensin-II Site One Receptor. J. Comput. Aid.
Mol. Des. 1994, 8, 491-512. (b) Mantlo, N. B.; Chakravarty, P. K.;
Ondeyka, D. L.; Siegl, P. K. S.; Chang, R. S.; Lotti, V. J.; Faust, K.
A.; Chen, T.-B.; Schorn, T. W.; Sweet, C. S.; Emmert, S. E.; Patchett,
A. A.; Greenlee, W. J. Potent, Orally Active Imidazo[4,5-b]pyridine-
(37) Barker, S.; Marchant, W.; Clark, A. J. L.; Jimenez, E.; Marsigliante,
S.; Montiel, M.; Vinson, G. P. Comparison of COS Cells Transfected
AT1A and AT1B Angiotensin II Receptors and Angiotensin II Receptor
Isoforms in Rat Tissues Using Isoelectric Focusing. Biochem.
Biophys. Res. Commun. 1993, 192, 392-398.
JM050232E